Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

2(20%)

Results Posted

75%(3 trials)

Terminated

1(10%)

Phase Distribution

Ph not_applicable

30%

Ph phase_3

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 3Large-scale testing

6(66.7%)

N/ANon-phased studies

3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(4)

Terminated(2)

Other(2)

Detailed Status

Completed4

Active, not recruiting2

unknown1

Suspended1

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 3

Trials by Phase

Phase 36 (66.7%)

N/A3 (33.3%)

Trials by Status

unknown110%

active_not_recruiting220%

completed440%

suspended110%

terminated110%

withdrawn110%

Recent Activity

2 active trials

Showing 5 of 10

completedphase_3

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690

active_not_recruitingnot_applicable

Clinical Trials (10)

Showing 10 of 10 trials

NCT00066690Phase 3

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Completed

NCT02760849Not Applicable

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Active Not Recruiting

NCT05863676

Ovarian Tissue Cryopreservation in the Setting of Gender-affirming Therapy

Active Not Recruiting

NCT05434936Not Applicable

Ovarian Tissue Cryopreservation for Fertility Preservation in Girls and Women

Suspended

NCT00066807Phase 3

Premenopausal Endocrine Responsive Chemotherapy Trial

Terminated

NCT00293540Phase 3

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

Completed

NCT00002580Phase 3

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

Completed

NCT00084370Not Applicable

Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy

Withdrawn

NCT00002460Phase 3

Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer

Unknown

NCT00002582Phase 3

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Completed

All 10 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 10